Pharmafile Logo
Pharmafocus logo
Advanced Search

enzalutamide

Showing 3 posts of 3 posts found.

logo

Phase III trial initiated for enzalutamide in treatment of prostate cancer

March 24, 2016
Research and Development Astellas, Medivation, arches, clinical trial, enzalutamide, phase 3, phase III, prostate cancer

Astellas Pharma (TSE: 4503) and Medivation (NASDAQ:MDVN) have announced the initiation of the ARCHES Phase III clinical trial to evaluate …

News
Afinitor image

Mixed bag for Novartis and Astellas in breast cancer

December 15, 2014
Research and Development, Sales and Marketing Afinitor, Astellas, Novartis, Xtandi, enzalutamide, everolimus

Preliminary results from a Phase II trial of Astellas’ Xtandi (enzalutamide) show positive benefits for the prostate cancer drug when …

News

Astellas submits new prostate cancer drug to EMA

June 28, 2012
Research and Development, Sales and Marketing Astellas, EMA, Medivation, NICE, Zytiga, enzalutamide

Astellas has submitted its investigational prostate cancer drug enzalutamide to the European Medicines Agency. Enzalutamide is a once-daily pill that works …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026